États-Unis · Magazines éco · Inc.

This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

Publié par Inc. · États-Unis il y a 2 h

A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.

Lire l'article complet sur Inc. Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.inc.com)

This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

À lire aussi

12 things to do in Istanbul, from Hagia Sophia to a Bosphorus ferry

A $44 million superhero horror film won the box office this weekend. A $7 million documentary came within $5 million of beating it

Stocks Start a Big Week With Solid Gains: Stock Market Today

Microsoft offers voluntary buyouts to 60,000 employees as tech giant reshapes its workforce

Entrepreneurship might be the key to a longer life

Megan Thee Stallion Says This Is the ‘Biggest Mistake’ She Made Early in Her Career — And How She Fixed It

This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

Partager

À lire aussi

12 things to do in Istanbul, from Hagia Sophia to a Bosphorus ferry

A $44 million superhero horror film won the box office this weekend. A $7 million documentary came within $5 million of beating it

Stocks Start a Big Week With Solid Gains: Stock Market Today

Microsoft offers voluntary buyouts to 60,000 employees as tech giant reshapes its workforce

Entrepreneurship might be the key to a longer life

Megan Thee Stallion Says This Is the ‘Biggest Mistake’ She Made Early in Her Career — And How She Fixed It